Genentech, Inc.1 Founded: 19761
1 DNA Way Mailstop 258A IPO: 1980
South San Francisco, CA 94080 website: www.gene.com
Fax: (650) 225-4630
NASDAQ-GM: NYSE: DNA2
NAICS: 325412; Pharmaceutical preparation manufacturing 2
SIC: Pharmaceutical preparations 28342
Principal lines of business; Stem Cells treating in area of oncology and autoimmune pharmaceuticals2
Fiscal Period: Most recent quarter (Q4, 2008)
State Actual End Date: December 31st
State Reporting Unit: billions
Summary Income3 Summary Balance Sheet3
Total Revenues: 13.418 Total Current Assets: 10.1
Total Operating Expense: 6.75 Total Assets: 21.8
Net Income (after taxes): 3.43 Total Current Liabilities: 3.1
Basic/Diluted EPS: 3.25 Total Long Term Debt: 2.33
Quarterly Revenue Growth: 24% Total Liabilities: 6.12
Total Equity: 15.7
Summary Cash Flow3 Total Liabilities & Shareholders Equity: 21.82
Cash from Operating Activities 3.96 Total Common Shares Outstanding: 21million
Cash from Investing Activities (1.67) Total Cash/Share: 3.25
Cash from Financing Activities (0.269) Total Debt/Equity: N/A
Net Change in Cash 2.02
P/E (intraday): 24.6
Market Capitalization: $ 99.91billion
Most Recent Closing Price: $95 closing price for March 26 2009.
Works in research and development of variety of pharmaceuticals and pharmaceutical components the company aims and interests are in treatment of life threatening illnesses and diseases. Its main focus has been greatly on cancer.
Rituxan (non-Hodgkins lymphoma)
Avastin (colorectal and lung cancers)
Herceptin (breast cancer)
Tarceva (lung cancer)
Xeloda (metastatic colorectal cancer)
Zelboraf (inoperable melanoma)
Age related diseases
Genentech has other variety products that it has produced and continues to conduct research and trials for new products.
Earnings from specific product sales3
Nutropin products: $ 358000000
Thrombolytics:$275000000; Sales per period ending 31st December 2008.
The competing drugs are grouped according to their disease targets and the adverse effects and effectiveness of the drugs as well as mechanism of action.
Earnings from Overall Product Sales3
Principal Strategic Partners6
Most Recent Significant Company News4
February 6, 2015, The FDA provided the good news that Genentechs Lucentis had been approved for treatment of diabetic retinopathy in patients with diabetic macular edema. This news marked another first in Genentechs many firsts in development of drugs that assist in life threatening illnesses. Diabetic macular edema is a leading cause of blindness which can occur during diabetic retinopathy. Prior to the approval, there was no approved medication for the condition. This is good news to the patients and the health care fraternity as well as Genentechs investors and share holders. The recent approval further strengthens Genentechs market hold and expands its market share. This is an approval that comes at a time when the company is continuing research in better and more effective and therapeutic approaches and drugs in treatment of cancer. This success hence provides future hope in the companys growth.
Recent analysis has put a bright future in the research of a cancer treatment by the pharmaceutical company. Genentech had its ground breaking discovery by first developing a drug that targeted the cancer tumors while leaving the healthy cells to thrive. In their recent studies, Genentech has been working towards developing a drug which is able to stimulate the immune system to attack the tumors as it does to other infections such as viruses.
This is a great opportunity for Genentech to open a while new play ground and bring in a new way in the fight against cancer. The company has so far been able to attain good results with some patients showing shrinkage of their tumors. There however, have been a few setbacks with some showing delayed response to the said medications for yet to be established reasons.
My type of portfolio is based on strong companies that have had a strong reputation in certain various fields. Genentech presents a business opportunity that is tested and has managed to survive and remain profitable for many years. Genentechs has made tremendous growth in the past years bringing in good profits and has working in progress that is very promising. Genentech is a company that is making what tomorrows patient will need today hence I would invest in its shares for the long term. The companys financial statements are healthy and indicate expected growth.
The company as well expanded and has through partnerships diverged into other personalized medical manufacturing such as pain treatment among others. The future prospects in Genentech are good. If the research on new form for cancer treatment drug which has so far shown some degree of success goes through, the shares in the company will shoot to higher prices.
Genentech is a pharmaceutical that is currently operating in a very competitive and demanding market. This is a market that is continuously changing as new inventions and approaches towards therapeutics are devised daily. Genentech business model from my point of view appears to be a model that is centered on research and innovation rather than capitalization. The company puts its resources in the development of new therapeutic approaches in treatment of life threatening diseases. Through research based innovation, the company ensures that it is a market leader by developing first brands of medicines with innovative mechanism of workings. Genentech model hence enables them to be a market leader in the development of cutting edge drugs, which has seen the company achieve many firsts in development of drugs.
The company as well employs a business model whereby it concentrates or has narrowed down its targeted production and research to a life threatening illnesses such as cancer while partnering with other companies to produce other medications such as analgesics. This allows the company to concentrate its research and development and specialize in one area and become a market leader in it.
8. Napodano, CFA. Avastin Vastly Improves Genentech Analyst Blog. Zacks Investment Research Analyst Blog 4 June 2008. Web. 9 May 2015.
Hi there! Click one of our representatives below and we will get back to you as soon as possible.